Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy)
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). The platform is commercially validated by well over $1.0 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, and others.